InspireMD Inc. Common Stock (NSPR)

FairStock Score: 44/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach InspireMD as a Graham-style analyst: show me durable earnings and a margin of safety. This is a 127-employee medical-device company selling CGuard/MicroNet for carotid artery disease. The business is not yet self-sustaining. In FY2025, the year ended 2025-12-31, revenue was $9.0M and net income was -$48.8M. In FY2024, revenue was $7.0M and net income was -$32.0M. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $1.8M and net income was -$14.3M, with diluted EPS of -$0.17. Revenue moved from $6.2M in FY2023 to $9.0M in FY2025, but net losses widened from -$19.9M to -$48.8M. TTM free cash flow is -$42.5M against a $23.2M market cap, a FairStock FCF yield of -182.7%. The low D/E of 0.10 is a small comfort, but FairStock's ROE of -202.81% and ROCE of -85.85% show capital is being consumed, not compounded. The Piotroski F-Score of 2/9 and Altman Z-Score of -9.60 point to financial distress. At $0.50 on 2026-10-13, P/B is 0.75 (FairStock calculation), which might look asset-cheap, but book value is not worth much if cash keeps burning. There is no Lynch category because losses have occurred in each of the last four years. A medical-device moat depends on commercial adoption and execution; the figures do not demonstrate pricing power or a durable competitive advantage. I see a speculative turn-around, not a Graham bargain.

In plain English: InspireMD makes medical devices, including CGuard and MicroNet, to treat carotid artery disease. It is a very small company with sales that have grown annually but losses that are much larger and heavy cash use. At $0.50 on 2026-10-13, the price looks low, but because the company keeps losing money, it does not look clearly cheap on its numbers; it looks risky and speculative.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer